Edwards Lifesciences' PROGRESS study shows TAVR cuts death or heart failure endpoint by 33%

Edwards Lifesciences announced its PROGRESS trial showed transcatheter aortic valve replacement cut the composite endpoint of death or heart failure by 33% versus clinical surveillance in patients with moderate aortic stenosis and at-risk features, and lowered heart failure hospitalizations by over 50%.

Detected & updated continuously · Source: Nebula